I know it is difficult time for you and you need make decision. I try don't give comment about
Provenge if somebody in process of making decision, but in your case ( you tell you live along ) I will brake my rule.
You maybe already know that the best give Provenge first in mHRPC, before Zytiga, Chemo, Xtandi.
I want lay down to you some facts about
Provenge for patients in your situation after Chemo:
A treatment effect of Provenge was observed in both patients with and without CHEMO;At GU Cancers Symposium analysis of the PROCEED trial showed that patients previously exposed to docetaxel ( chemo) derived a similar benefit from the vaccine as those who were docetaxel-naïve.
The analysis of the same patient population compared the immunologic effects of the vaccine in patients previously exposed to docetaxel versus those who were docetaxel-naïve upon entry to the registry [Abstract 30]. These data were presented by Oliver Sartor, MD, professor of Medicine and Urology at Tulane University School of Medicine, New Orleans, Louisianna.
"Sartor noted that in the IMPACT trial, the use of docetaxel was prohibited within 3 months prior to registration, but there was no restriction on docetaxel use in the real-world PROCEED registry.
Of the 560 patients enrolled in the study, 82 (15%) previously had received docetaxel and 474 (85%) had received no docetaxel; the docetaxel stop date was not available for 4 patients. Of the patients who had received docetaxel, 14 patients received docetaxel for 90 days or less before initiation of sipuleucel-T, and 68 patients received docetaxel more than 90 days before initiation of the vaccine.Baseline demographics and disease characteristics were different in patients with and without prior docetaxel exposure. Product parameters of Provenge, including APC and TNC counts and APC activation, were comparable in both groups independent of prior docetaxel use.“Sipuleucel-T stimulated a robust immune response that is consistent with immune prime-boost independent of prior docetaxel exposure,” the authors wrote..."www.onclive.com/publications/urologists-in-cancer-care/2013/april-2013/use-of-sipuleucel-t-refined/1 Researchers are interested in the combination of AR antagonists with novel agents, such as sipuleucel-T (Provenge) and radium-223.
In general, the agents approved to treat prostate cancer have varying mechanisms of action and favorable toxicity profiles, which provides an abundance of potential for novel combinations." ( No yet trial).
So maybe you can try Radium-223 after Provenge, if you want postpone Jevtana a little later. ( talk with your doctor about
Trial in Georgia Health Sciences University: ( if you want to give thoughts to it, no Placebo group )
There will be three arms: One will be Provenge alone, one will be Provenge plus the CT-011, and one will be the combination Provenge, CT-011 and cyclophosphamide.This study hopes to show that a therapeutic vaccine plus combination (of CT-011 to prevents the tumor's PDL-1 from binding to the T-cell PD-1 receptor and cyclophosphamide to decreases suppressor T-cells, which inhibit the immune system from acting against the tumor.) might be better than giving the vaccine as a single agent.
You can read information here: clinicaltrials.gov/ct2/show/NCT01420965?term=Provenge&rank=2
Regardless collection site- call Dendrion, they should give you all information ( somewhere I read, no sure, that they also provide transportation, who need it, you can ask them about
A lot of information on Provenge threat here:www.healingwell.com/community/default.aspx?f=35&m=2487796
Remember Provenge has short-treatment course, almost no SE, non-overlapping MOA, so why it is good add to your arsenal to fight with prostate cancer.
And last you can always go to Jevtana but it can be late for Provenge after .
My best to you and take care yourself
Post Edited (HOPENEVERDIE) : 8/29/2013 3:36:36 PM (GMT-6)